Market Recap — August 21, 2026
Today's running recap of insider activity, SEC filings, and market-moving news. Updates throughout the trading day.
Last updated Aug 21, 2026, 10:25 AM ET · updates through the trading day
Top Importance Today
Filings and news with the highest AI-ranked importance score.
CDT Equity details highly dilutive 20% stake in AI firm Sarborg, valued at $115M
Werewolf Files Full Merger Agreement with Ambros: $500M Reverse Merger, $150M PIPE, and CVR for Legacy Assets
Werewolf Therapeutics to Merge with Ambros Therapeutics in $500M All-Stock Deal with $150M PIPE
Synergy CHC Faces Nasdaq Delisting Notice Over Late Q2 10-Q
Gossamer Bio Secures Up to $250M Structured Private Placement to Fund Seralutinib Through FDA Approval
Werewolf Therapeutics to Merge with Ambros, Raises $150M in Oversubscribed Placement
Gossamer Bio Secures Up to $250M to Fund Seralutinib Through FDA Approval
Forbright Sells D.C.-Area Branches and $750M Deposits to Trustar for $19M Premium
CDT Equity Files Sarborg Financials: $30.9M Warrant Dilution and Sarborg's Own Going Concern Warning
Grown Rogue Enters New York via PharmaCann Asset Deal with $15M Project Financing
Direct Digital Holdings Buys Time with Lender Waiver and Nasdaq Extension
Werewolf Shares Double as Reverse Merger Details Emerge: $47.5M Implied Value, 6.8% Stake
Largest Open-Market Insider Buys
Form 4 open-market purchases ranked by dollar amount.
No open-market insider buys reported on this date.
Largest Open-Market Insider Sells
Form 4 open-market sales ranked by dollar amount.
No open-market insider sells reported on this date.
Notable 8-Ks and News
Material events and breaking news with importance score 6 or higher.
Werewolf Therapeutics to Merge with Ambros Therapeutics in $500M All-Stock Deal with $150M PIPE
Synergy CHC Faces Nasdaq Delisting Notice Over Late Q2 10-Q
Gossamer Bio Secures Up to $250M Structured Private Placement to Fund Seralutinib Through FDA Approval
Werewolf Therapeutics to Merge with Ambros, Raises $150M in Oversubscribed Placement
Gossamer Bio Secures Up to $250M to Fund Seralutinib Through FDA Approval
Forbright Sells D.C.-Area Branches and $750M Deposits to Trustar for $19M Premium
Grown Rogue Enters New York via PharmaCann Asset Deal with $15M Project Financing
Direct Digital Holdings Buys Time with Lender Waiver and Nasdaq Extension
Werewolf Shares Double as Reverse Merger Details Emerge: $47.5M Implied Value, 6.8% Stake
Bitcoin's 20% Surge Puts Strategy Back in the Green With $1.4B Unrealized Gain
Form 144 Notices
Notices that restricted shares may be sold soon — often a precursor to insider selling.
No Form 144 notices filed on this date.
Day boundary: 00:00 ET (America/New_York). Filings accepted late may appear in the next day's recap.